{"groups":[{"description":"Participants with Ewing sarcoma received lenvatinib 14 mg/m\\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.","id":"FG000","title":"Ewing Sarcoma"},{"description":"Participants with rhabdomyosarcoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"FG001","title":"Rhabdomyosarcoma"},{"description":"Participants with high grade glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"FG002","title":"High Grade Glioma"},{"description":"Participants with diffuse midline glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"FG003","title":"Diffuse Midline Glioma"},{"description":"Participants with medulloblastoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"FG004","title":"Medulloblastoma"},{"description":"Participants with ependymoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"FG005","title":"Ependymoma"},{"description":"Participants with other solid tumors received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"FG006","title":"Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"55"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Withdrawal by Parent/Guardian"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"10"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"66"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"66"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were recruited to tumor cohorts of Ewing Sarcoma, Rhabdomyosarcoma, High Grade Glioma, and Other Solid Tumors Excluding Osteosarcoma. Enrollment to the protocol pre-specified tumor cohort of \"Other Solid Tumors Excluding Osteosarcoma\" was further expanded into categories of Diffuse midline glioma, Medulloblastoma, and Ependymoma."}